Impact of cyclosporine dose on long-term outcome after heart transplantation

Transplant Proc. 1994 Oct;26(5):2710-2.

Authors

H Valantine¹, S Hunt, P Gamberg, J Miller, H Luikart

Affiliation

¹ Division of Cardiovascular Medicine, Stanford University School of Medicine, California 94305-5246.

PMID: 7940848

No abstract available

Publication types

Comparative Study

MeSH terms

Actuarial Analysis
Antilymphocyte Serum / therapeutic use
Azathioprine / therapeutic use
Coronary Disease / epidemiology
Cyclosporine / adverse effects
Cyclosporine / therapeutic use*
Dose-Response Relationship, Drug
Follow-Up Studies
Graft Rejection / epidemiology
Heart Transplantation / immunology
Heart Transplantation / mortality
Heart Transplantation / physiology*
Humans
Immunosuppression Therapy / adverse effects
Immunosuppression Therapy / methods
Muromonab-CD3 / therapeutic use
Prevalence
Probability
Retrospective Studies
Survival Rate
Time Factors
Treatment Outcome

Substances

Antilymphocyte Serum
Muromonab-CD3
Cyclosporine
Azathioprine